- Home
- DVAX vs CSR Comparison
DVAX vs CSR Comparison
Compare DVAX & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- CSR
- Stock Information
- Founded
- DVAX 1996
- CSR 1970
- Country
- DVAX United States
- CSR United States
- Employees
- DVAX N/A
- CSR N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- CSR Real Estate Investment Trusts
- Sector
- DVAX Health Care
- CSR Real Estate
- Exchange
- DVAX Nasdaq
- CSR Nasdaq
- Market Cap
- DVAX 1.2B
- CSR 965.4M
- IPO Year
- DVAX 2004
- CSR N/A
- Fundamental
- Price
- DVAX $10.44
- CSR $60.22
- Analyst Decision
- DVAX Buy
- CSR Buy
- Analyst Count
- DVAX 4
- CSR 7
- Target Price
- DVAX $26.50
- CSR $68.57
- AVG Volume (30 Days)
- DVAX 1.3M
- CSR 131.3K
- Earning Date
- DVAX 11-05-2025
- CSR 11-03-2025
- Dividend Yield
- DVAX N/A
- CSR 5.16%
- EPS Growth
- DVAX N/A
- CSR N/A
- EPS
- DVAX N/A
- CSR N/A
- Revenue
- DVAX $316,268,000.00
- CSR $267,076,000.00
- Revenue This Year
- DVAX $23.23
- CSR $5.79
- Revenue Next Year
- DVAX $16.57
- CSR $2.29
- P/E Ratio
- DVAX N/A
- CSR N/A
- Revenue Growth
- DVAX 26.66
- CSR 3.44
- 52 Week Low
- DVAX $9.20
- CSR $52.76
- 52 Week High
- DVAX $14.63
- CSR $75.92
- Technical
- Relative Strength Index (RSI)
- DVAX 58.99
- CSR 57.04
- Support Level
- DVAX $10.03
- CSR $58.63
- Resistance Level
- DVAX $10.59
- CSR $61.02
- Average True Range (ATR)
- DVAX 0.22
- CSR 1.46
- MACD
- DVAX 0.06
- CSR 0.04
- Stochastic Oscillator
- DVAX 81.25
- CSR 77.47
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.